Reply: Reversal of structural abnormalities with elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: the earlier you start, the better the outcome will be!
- PMID: 39326907
- DOI: 10.1183/13993003.01247-2024
Reply: Reversal of structural abnormalities with elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: the earlier you start, the better the outcome will be!
Conflict of interest statement
Conflict of interest: P-R. Burgel reports support for the present study from Vaincre la Mucoviscidose, grants from Boehringer Ingelheim, GSK and Vertex, consultancy fees from Boehringer Ingelheim, GSK, AstraZeneca, Vertex, Chiesi, Pfizer, Novartis, Zambon and Insmed, and payment or honoraria for lectures, presentations, manuscript writing or educational events from Boehringer Ingelheim, GSK, AstraZeneca, Vertex, Chiesi, Pfizer, Novartis, Zambon and Insmed. G. Chassagnon reports payment or honoraria for lectures, presentations, manuscript writing or educational events from Chiesi and Boehringer Ingelheim.
Comment on
-
Reversal of cylindrical bronchial dilatations in a subset of adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.Eur Respir J. 2024 Mar 28;63(3):2301794. doi: 10.1183/13993003.01794-2023. Print 2024 Mar. Eur Respir J. 2024. PMID: 38331460
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical